TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Quantum Biopharma ( (TSE:QNTM) ) is now available.
On November 26, 2025, Quantum BioPharma announced that CTV News’ investigative program W5 will feature a three-part series on the company’s allegations of stock market manipulation. The series, beginning today, investigates ‘stock spoofing,’ a tactic Quantum claims derailed their multiple sclerosis research, leading to a $700 million lawsuit against CIBC and RBC. This media exposure could impact Quantum’s industry positioning by highlighting the challenges faced due to alleged market manipulation, potentially influencing stakeholders and raising awareness about the illegal practice.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Their lead compound, Lucid-MS, aims to prevent and reverse myelin degradation in multiple sclerosis. The company also holds strategic investments and retains a stake in Unbuzzd Wellness Inc., which markets an OTC product for alcohol misuse.
Average Trading Volume: 2,882
Technical Sentiment Signal: Sell
Current Market Cap: C$43.13M
See more data about QNTM stock on TipRanks’ Stock Analysis page.